Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irwin Lucki

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2009
Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in miceGeorgia E Hodes, Tiffany E Hill-Smith, Raymond F Suckow, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 20, 2009
Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto ratsGregory V Carr, Debra A Bangasser, Thelma Bethea, et al.
Frontiers in Synaptic Neuroscience|November 15, 2018
Ketamine Reverses Lateral Habenula Neuronal Dysfunction and Behavioral Immobility in the Forced Swim Test Following Maternal Deprivation in Late Adolescent RatsRyan D Shepard, Ludovic D Langlois, Caroline A Browne, et al.
Journal of the American Pharmacists Association : Japha|May 30, 2025
A comparison of the essential medicines lists of the U.S. Department of Health and Human Services, the U.S. Department of Defense, the U.S. Food and Drug Administration, and the World Health OrganizationMiranda Lynn Janvrin, Amandari Kanagaratnam, Victor A Suarez, et al.
Experimental Neurology|December 30, 2021
Long-term increase in sensitivity to ketamine's behavioral effects in mice exposed to mild blast induced traumatic brain injuryCaroline A Browne, Hildegard A Wulf, Moriah L Jacobson, et al.
Diabetes Care|July 26, 2014
NIDDK international conference report on diabetes and depression: current understanding and future directionsRichard I G Holt, Mary de Groot, Irwin Lucki, et al.
Psychopharmacology|February 24, 2007
Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension testOlivia F O'Leary, Anita J Bechtholt, James J Crowley, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2002
Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonistMichelle E Page, John F Cryan, Arthur Sullivan, et al.
Psychopharmacology|February 9, 2013
Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expressionRobert E Featherstone, Valerie M Tatard-Leitman, Jimmy D Suh, et al.
Brain Research|April 25, 2008
Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatmentsDarrick T Balu, Brian A Hoshaw, Jessica E Malberg, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2009
Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in miceGeorgia E Hodes, Tiffany E Hill-Smith, Raymond F Suckow, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 20, 2009
Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto ratsGregory V Carr, Debra A Bangasser, Thelma Bethea, et al.
Frontiers in Synaptic Neuroscience|November 15, 2018
Ketamine Reverses Lateral Habenula Neuronal Dysfunction and Behavioral Immobility in the Forced Swim Test Following Maternal Deprivation in Late Adolescent RatsRyan D Shepard, Ludovic D Langlois, Caroline A Browne, et al.
Journal of the American Pharmacists Association : Japha|May 30, 2025
A comparison of the essential medicines lists of the U.S. Department of Health and Human Services, the U.S. Department of Defense, the U.S. Food and Drug Administration, and the World Health OrganizationMiranda Lynn Janvrin, Amandari Kanagaratnam, Victor A Suarez, et al.
Experimental Neurology|December 30, 2021
Long-term increase in sensitivity to ketamine's behavioral effects in mice exposed to mild blast induced traumatic brain injuryCaroline A Browne, Hildegard A Wulf, Moriah L Jacobson, et al.
Diabetes Care|July 26, 2014
NIDDK international conference report on diabetes and depression: current understanding and future directionsRichard I G Holt, Mary de Groot, Irwin Lucki, et al.
Psychopharmacology|February 24, 2007
Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension testOlivia F O'Leary, Anita J Bechtholt, James J Crowley, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2002
Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonistMichelle E Page, John F Cryan, Arthur Sullivan, et al.
Psychopharmacology|February 9, 2013
Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expressionRobert E Featherstone, Valerie M Tatard-Leitman, Jimmy D Suh, et al.
Brain Research|April 25, 2008
Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatmentsDarrick T Balu, Brian A Hoshaw, Jessica E Malberg, et al.
Pageof 10